J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns

The pharmaceutical business continues to withstand the arrival of more Remicade biosimilars and the firm maintains it will have solid growth even with generic competition to its Zytiga.

Economics graph

The oncology franchise carried growth for Johnson & Johnson in the third quarter and continues to increase its prominence for J&J’s pharmaceuticals business overall. But some of the cancer growth will be dimmed by potential generic competition to its prostate cancer blockbuster Zytiga.

While Zytiga comprises about 5% of J&J’s pharmaceutical sales, according to a Morningstar estimate, J&J reported its pharma segment growth...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.